Jacqui Rowbottom
Impact in
- Oncology top 5%
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment
Papers in
- Oncology 3
- PARP inhibition in cancer therapy 2
- HER2/EGFR in Cancer Research 1
-
- Lung Cancer Treatments and Mutations 2
- Gastric Cancer Management and Outcomes 1
- Co-authors
- Barbara Schmalfeldt (1 shared paper)Zhimin Shao (1 shared paper)Ana Benzaquén Vallejos (1 shared paper)Peter Vuylsteke (1 shared paper)Nicoletta Colombo (1 shared paper)Ekaterina Trishkina (1 shared paper)Lynda M Grinsted (1 shared paper)Brian Andrew Dougherty (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)The Lancet Oncology (1 paper)Annals of Oncology (1 paper)The Lancet (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesUnited KingdomJapan
In The Last Decade
Jacqui Rowbottom
6 papers receiving 1.5k citations
Jacqui Rowbottom's Hit Papers
Peers
Comparison fields: 5 of 62
- Oncology 926
- Reproductive Medicine 179
- Pulmonary and Respiratory Medicine 612
- Cancer Research 244
- Molecular Biology 424
Countries citing papers authored by Jacqui Rowbottom
This map shows the geographic impact of Jacqui Rowbottom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqui Rowbottom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqui Rowbottom more than expected).
Fields of papers citing papers by Jacqui Rowbottom
This network shows the impact of papers produced by Jacqui Rowbottom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqui Rowbottom. The network helps show where Jacqui Rowbottom may publish in the future.
Co-authors
The 25 scholars most cited alongside Jacqui Rowbottom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Hit paper breakdown → | 2014 | 477 |
| 2 | Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2016 | 443 |
| 3 | 2011 | 254 | |
| 4 | 2015 | 245 | |
| 5 | 2005 | 167 | |
| 6 | 2021 | 3 |
About Jacqui Rowbottom
Jacqui Rowbottom is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Insect Science, Renewable Energy, Sustainability and the Environment and Obstetrics and Gynecology, having authored 6 papers that have together received 1.6k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (2 papers), Lung Cancer Treatments and Mutations (2 papers), Gastric Cancer Management and Outcomes (1 paper) and HER2/EGFR in Cancer Research (1 paper). The work is most often cited by research in Oncology (926 citations), Reproductive Medicine (179 citations), Pulmonary and Respiratory Medicine (612 citations), Cancer Research (244 citations) and Molecular Biology (424 citations). Jacqui Rowbottom has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Barbara Schmalfeldt, Zhimin Shao, Ana Benzaquén Vallejos, Peter Vuylsteke, Nicoletta Colombo, Ekaterina Trishkina, Lynda M Grinsted, Brian Andrew Dougherty, Ron H. J. Mathijssen and Mary A. Stuart. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology, Annals of Oncology, The Lancet and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.